Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

European Respiratory Journal

Volumn 39, Issue 1, 2012, Pages 9-28

  Berghmans, T ^a   Pasleau, F ^b   Paesmans, M ^a   Bonduelle, Y ^c   Cadranel, J ^d   Toth, I Cs ^a   Garcia, C ^a   Giner, V ^e   Holbrechts, S ^f   Lafitte, J J ^g   Lecomte, J ^h   Louviaux, I ^c   Markiewicz, E ^a   Meert, A P ^a   Richez, M ^c   Roelandts, M ^a   Scherpereel, A ^g   Tulippe, Ch ⁱ   Van Houtte, P ^a   Van Schil, P ^c   Wachters, C ^a   Westeel, V ^j   Sculier, J P ^a   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c CH Peltzer La Tourelle ^*  (Belgium)

^d HÔPITAL TENON   (France)

^e HOSPITAL DE SAGUNTO   (Spain)

^f Centre Hospitalier Universitaire Ambroise Pare   (Belgium)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h Centre Hospitalier Universitaire de Charleroi   (Belgium)

ⁱ Centre Hospitalier de Mouscron   (Belgium)

^j UNIVERSITY HOSPITAL OF BESANÇON   (France)

more..

Author keywords

Guidelines; Lung cancer; Surrogate; Survival; Systematic review

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEFITINIB; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; TOPOTECAN; UFT; VINCA ALKALOID;

ANALYTICAL PARAMETERS; ANEMIA; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CIRCULATING TUMOR CELL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; ENDOBRONCHIAL ULTRASONOGRAPHY; ESOPHAGOSCOPY; EVIDENCE BASED MEDICINE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL LITERATURE; MEDICAL SOCIETY; METHODOLOGY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEOMICS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TIME TO PROGRESSION; TREATMENT RESPONSE; VIDEO ASSISTED THORACOSCOPIC SURGERY;

BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; EUROPE; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PULMONARY MEDICINE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84855401607     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00190310     Document Type: Review

References (156)

1. Meert AP, Sculier JP. What has the meta-analysis contributed to today's standard of care in the treatment of thoracic malignancies? Lung Cancer 2008; 61: 141-151.
2. European Lung Cancer Working Party. Traitement des cancers bronchiques non à petites cellules résécables. Recommandations de pratique clinique de l'European Lung Cancer Working Party [Management of resectable non-small cell lung cancer. Guidelines of clinical practice made by the European Lung Cancer Working Party]. Rev Med Brux 2006; 27: 29-38.
3. European Lung Cancer Working Party. Traitement des cancers bronchiques non à petites cellules, non métastatiques et non résécable. Recommandations de pratique clinique de l'European Lung Cancer Working Party [Management of unresectable non-metastatic non-small cell lung cancer. Guidelines of clinical practice made by the European Lung Cancer Working Party]. Rev Med Brux 2006; 27: 152-161.
4. European Lung Cancer Working Party. Les recommandations de pratique clinique de l'European Lung Cancer Working Party. Cancers bronchiques non à petites cellules: III. Maladies avancées (métastatiques) [Treatment of non-small cell lung cancer: advanced (metastatic) disease. Guidelines of clinical practice made by the European Lung Cancer Working Party]. Rev Med Brux 2007; 28: 495-511.
5. European Lung Cancer Working Party. Traitement du cancer bronchique à petites cellules: maladies limitées. Les recommandations de pratique clinique de l'European Lung Cancer Working Party [Treatment of small cell lung cancer: limited diseases. Guidelines of clinical practice made by the European Lung Cancer Working Party]. Rev Med Brux 2008; 29: 159-167.
6. European Lung Cancer Working Party. Traitement du cancer bronchique à petites cellules: maladies étendues. Les recommandations de pratique clinique de l'European Lung Cancer Working Party [Treatment of small cell lung cancer: extensive diseases. Guidelines of clinical practice made by the European Lung Cancer Working Party]. Rev Med Brux 2008; 29: 455-470.
7. Prentice RL. Surrogate endpoints in clinical trials, definition and operational criteria. Stat Med 1989; 8: 431-440. (Pubitemid 19105891)
8. Buyse M, Sargent DJ, Grothey A, et al. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 2010; 7: 309-317.
9. Sackett DL, Straus SE, Richardson WS, et al. Evidence-Based Medicine. How to Practice and Teach EBM. Asking Answerable Clinical Questions. 2nd Edn. Edinburgh, Churchill Livingstone, 2000; pp. 13-27.
10. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 225S-233S. (Pubitemid 16138265)
11. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717. (Pubitemid 27260107)
12. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Clinical Trials Endpoints For the Approval of Cancer Drugs and Biologics. Rockville, Food and Drug Administration, 2007.
14. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1979.
15. Warren W. Historical facets of thoracic surgery emphasizing lung cancer. In: Gruhn JG, Rosen ST, eds. Lung Cancer. The Evolution of Concepts. New York, Field and Wood, 1989; pp. 73-106.
16. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005; 49: 13-23. (Pubitemid 40798089)
17. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007; 369: 1929-1937. (Pubitemid 46874559)
18. Damstrup L, Poulsen HS. Review of the curative role of radiotherapy in the treatment of non-small cell lung cancer. Lung Cancer 1994; 11: 153-178. (Pubitemid 24289169)
19. Jassem J. The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol 2007; 83: 203-213. (Pubitemid 46776921)
20. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899-909.
21. Sculier JP, Berghmans T, Paesmans M, et al. La place de la chimiotherapie dans le traitement des cancers bronchiques non a petites cellules, non metastatiques [The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers]. Rev Med Brux 2001; 22: 477-487. (Pubitemid 34032151)
22. Rakovitch E, Tsao M, Ung Y, et al. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 2004; 58: 196-203. (Pubitemid 38010354)
23. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995; 76: 593-601.
24. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996; 125: 723-729. (Pubitemid 126450359)
25. Auperin A, Le PC, Pignon JP, et al. Concomitant radiochemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006; 17: 473-483. (Pubitemid 43329586)
26. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21. (Pubitemid 23183916)
27. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-1872. (Pubitemid 23304609)
28. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-865. (Pubitemid 24278896)
29. Sculier JP, Berghmans T, Castaigne A, et al. Best supportive care or chemotherapy for stage IV non small cell lung cancer. In: VanHoutte P, Klastersky J, Rocmans P, eds. Progress and Perspectives in Lung Cancer. Berlin, Springer Verlag, 1999; pp. 199-207.
30. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103. (Pubitemid 30324363)
31. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. (Pubitemid 41058344)
32. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969; 46: 516-525.
33. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30: 23-36.
34. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83: 8-15.
35. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10: 890-895.
36. Luce S, Paesmans M, Berghmans T, et al. Revue critique des etudes randomisees evaluant le role de la radiotherapie thoracique adjuvante a la chimiotherapie dans le traitement du cancer bronchique a petites cellules au stade limite [Critical review of the randomized trials assessing the role of adjuvant thoracic irradiation and chemotherapy in the treatment of limited-stage small cell lung cancer]. Rev Mal Respir 1998; 15: 633-641. (Pubitemid 28509141)
37. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618-1624.
38. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-5447. (Pubitemid 46623178)
39. Effets des anticancéreux sur la durée de survie: souvent mal évalués [Effect of anticancer drugs on survival duration: frequently poorly assessed]. La Revue Prescrire 2009; 29: 218-221.
40. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006; 7: 741-746. (Pubitemid 44283658)
41. Hotta K, Fujiwara Y, Matsuo K, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 311-317.
42. Buyse ME, Squifflet P, Laporte S, et al. Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2,838 patients randomized in 7 trials. J Clin Oncol 2008; 26: Suppl. 15, 428S.
43. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
44. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
45. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
46. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253. (Pubitemid 23008970)
47. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
48. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
49. Hotta K, Kiura K, Fujiwara Y, et al. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann Oncol 2009; 20: 829-834.
50. Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol 2007; 2: 402-407. (Pubitemid 47181694)
51. Kurata T, Matsuo K, Takada M, et al. Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? J Thorac Oncol 2006; 1: 684-691. (Pubitemid 47163957)
52. Sekine I, Kubota K, Nishiwaki Y, et al. Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer. Ann Oncol 1998; 9: 1079-1084. (Pubitemid 28518145)
53. Shanafelt TD, Loprinzi C, Marks R, et al. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004; 22: 1966-1974. (Pubitemid 41095190)
54. Tsujino K, Kawaguchi T, Kubo A, et al. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 2009; 4: 994-1001.
55. Lara PN Jr, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008; 26: 463-467. (Pubitemid 351171700)
56. Yamamoto N, Nambu Y, Fujimoto T, et al. A landmark point analysis with cytotoxic agents for advanced NSCLC. J Thorac Oncol 2009; 4: 697-701.
57. Paesmans M, Sculier JP, Libert P, et al. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer 1997; 33: 2326-2332. (Pubitemid 28129171)
58. Lebeau B, Chastang C, Schuller MP, et al. Chimiotherapie des cancers bronchiques a petites cellules. Importance pronostique d'une reponse complete (1,280 patients). Groupe Petites Cellules [Chemotherapy of small cell bronchial cancers. Prognostic importance of complete response (1,280 patients). Groupe Petites Cellules]. Presse Med 1995; 24: 217-221.
59. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-253. (Pubitemid 34032618)
60. Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003; 125: 254-260. (Pubitemid 36228303)
61. Sculier JP, Paesmans M, Lafitte JJ, et al. Prognostic factors analysis for response to chemotheray and survival in a prospective cohort of patients with unresectable locoregional non small cell lung cancer initially treated by induction chemotherapy. Rev Oncologia 1999; 1: 92-100.
62. Groen HJ, van der Leest AH, Fokkema E, et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 2004; 15: 427-432. (Pubitemid 38444545)
63. Crino L, Latini P, Meacci M, et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 1993; 4: 847-851. (Pubitemid 24032091)
64. Huber RM, Flentje M, Schmidt M, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 2006; 24: 4397-4404. (Pubitemid 46630977)
65. Joss RA, Alberto P, Bleher EA, et al. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1994; 5: 921-928.
66. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006; 94: 1099-1106.
67. Comella P, Scoppa G, Daponte A, et al. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer. Cancer 1994; 74: 1874-1881. (Pubitemid 24301847)
68. Lorent N, De Leyn P, Lievens Y, et al. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004; 15: 1645-1653. (Pubitemid 39562605)
69. Maurel J, Martinez-Trufero J, Artal A, et al. Prognostic impact of bulky mediastinal lymph nodes (N2 >2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy. Lung Cancer 2000; 30: 107-116.
70. Pignon T, Ruggieri S, Boutin C, et al. Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma. Cancer 1999; 85: 2144-2150. (Pubitemid 29215553)
71. Port JL, Korst RJ, Lee PC, et al. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg 2005; 79: 1686-1690. (Pubitemid 40614589)
72. Reboul F, Brewer Y, Vincent P, et al. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys 1996; 35: 343-350. (Pubitemid 26158757)
73. Tanvetyanon T, Eikman EA, Sommers E, et al. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol 2008; 26: 4610-4616.
74. Yokomise H, Gotoh M, Okamoto T, et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 133: 1179-1185. (Pubitemid 46635502)
75. Werner-Wasik M, Xiao Y, Pequignot E, et al. Assessment of lung cancer response after nonoperative therapy: tumour diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001; 51: 56-61. (Pubitemid 32758861)
76. Cortes J, Rodriguez J, az-Gonzalez JA, et al. Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer. Br J Cancer 2002; 87: 158-160.
77. Watanabe H, Yamamoto S, Kunitoh H, et al. Tumour response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci 2003; 94: 1015-1020. (Pubitemid 37508986)
78. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumours: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003; 33: 533-537. (Pubitemid 43115248)
79. Konishi K, Kuriyama K, Chino S, et al. [CT evaluation of response to chemotherapy and/or radiotherapy in primary lung cancer: comparison of response evaluation criteria in solid tumours (RECIST) and the WHO criteria, and comparison of both methods with the histological evaluation]. Nippon Igaku Hoshasen Gakkai Zasshi 2004; 64: 41-45.
80. MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21: 1285-1292. (Pubitemid 46606405)
81. 18F- fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97-106.
82. Hellwig D, Graeter TP, Ukena D, et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004; 128: 892-899. (Pubitemid 39575295)
83. Birch R, Omura GA, Greco FA, et al. Patterns of failure in combined chemotherapy and radiotherapy for limited small cell lung cancer: Southeastern Cancer Study Group experience. NCI Monogr 1988; 6: 265-270. (Pubitemid 18047998)
84. Cox JD, Byhardt R, Komaki R, et al. Interaction of thoracic irradiation and chemotherapy on local control and survival in small cell carcinoma of the lung. Cancer Treat Rep 1979; 63: 1251-1255. (Pubitemid 10187966)
85. Dosoretz DE, Galmarini D, Rubenstein JH, et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumour eradication. Int J Radiat Oncol Biol Phys 1993; 27: 507-516. (Pubitemid 23331115)
86. Perez CA, Bauer M, Edelstein S, et al. Impact of tumour control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12: 539-547. (Pubitemid 16081614)
87. Sculier JP, Paesmans M, Lafitte JJ, et al. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol 1999; 10: 295-303. (Pubitemid 29217220)
88. Moinpour CM, Lyons B, Grevstad PK, et al. Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res 2002; 11: 115-126. (Pubitemid 34438158)
89. Efficace F, Bottomley A, Smit EF, et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006; 17: 1698-1704. (Pubitemid 44680892)
90. Gotay CC, Kawamoto CT, Bottomley A, et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008; 26: 1355-1363.
91. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376. (Pubitemid 23073154)
92. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994; 30A: 635-642. (Pubitemid 24164250)
93. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199-220.
94. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144. (Pubitemid 28041591)
95. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002; 55: 285-295. (Pubitemid 34195525)
96. Victorson D, Soni M, Cella D. Metaanalysis of the correlation between radiographic tumour response and patient-reported outcomes. Cancer 2006; 106: 494-504. (Pubitemid 43157611)
97. Eton DT, Fairclough DL, Cella D, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003; 21: 1536-1543. (Pubitemid 46594107)
98. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005; 23: 2946-2954. (Pubitemid 46224113)
99. Natale RB. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Semin Oncol 2004; 31: 23-30. (Pubitemid 38879401)
100. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-794. (Pubitemid 41103589)
101. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784. (Pubitemid 41103588)
102. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99: 442-450. (Pubitemid 47073567)
103. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386.
104. De Leyn P, Lardinois D, Van Schil PE, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007; 32: 1-8. (Pubitemid 46874948)
105. de Cabanyes CS, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 2010; 5: 389-398.
106. Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006; 131: 1229-1235. (Pubitemid 43792421)
107. De Leyn P, Stroobants S, De WW, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006; 24: 3333-3339. (Pubitemid 46638886)
108. Jaklitsch MT, Gu L, Harpole DH, et al. Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA (N2) non-small cell lung cancer (NSCLC) results of CALGB 39803. J Clin Oncol 2005; 23: Suppl. 16, 636S.
109. Wittekind C, Compton CC, Greene FL, et al. TNM residual tumour classification revisited. Cancer 2002; 94: 2511-2516. (Pubitemid 34457134)
110. Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005; 49: 25-33. (Pubitemid 40798090)
111. Strand TE, Rostad H, Moller B, et al. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax 2006; 61: 710-715. (Pubitemid 44211780)
112. Suzuki K, Nagai K, Yoshida J, et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 1999; 86: 1976-1984.
113. Martin J, Ginsberg RJ, Venkatraman ES, et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 2002; 20: 1989-1995. (Pubitemid 34408788)
114. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009; 4: 792-801.
115. Birim O, Kappetein AP, van Klaveren RJ, et al. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 2006; 32: 12-23. (Pubitemid 43103982)
116. Pfannschmidt J, Muley T, Bulzebruck H, et al. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007; 55: 371-377. (Pubitemid 46331863)
117. Wisnivesky JP, Henschke C, McGinn T, et al. Prognosis of stage II non-small cell lung cancer according to tumour and nodal status at diagnosis. Lung Cancer 2005; 49: 181-186. (Pubitemid 40966745)
118. Gomez de la Cámara A, Lopez-Encuentra A, Ferrando P. Heterogeneity of prognostic profiles in non-small cell lung cancer: too many variables but a few relevant. Eur J Epidemiol 2005; 20: 907-914. (Pubitemid 41609490)
119. Koike T, Tsuchiya R, Goya T, et al. Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. J Thorac Oncol 2007; 2: 408-413. (Pubitemid 47181695)
120. Ohta M, Tsuchiya R, Shimoyama M, et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 1993; 106: 703-708. (Pubitemid 23310451)
121. A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur J Surg Oncol 1995; 21: 69-77.
122. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete
123. Wada H, Miyahara R, Tanaka F, et al. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 1999; 15: 438-443. (Pubitemid 29210345)
124. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95: 1453-1461. (Pubitemid 37279330)
125. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727. (Pubitemid 44283661)
126. Berghmans T, Dusart M, Paesmans M, et al. Primary tumour standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3: 6-12.
127. Paesmans M, Berghmans T, Dusart M, et al. Primary tumour standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2010; 5: 612-619.
128. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
129. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21: 2651-2657. (Pubitemid 46606307)
130. de Geus-Oei LF, van der Heijden HF, Visser EP, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007; 48: 1592-1598. (Pubitemid 47572705)
131. Dooms C, Verbeken E, Stroobants S, et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumour response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008; 26: 1128-1134.
132. de Geus-Oei LF, van der Heijden HF, Corstens FH, et al. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2007; 110: 1654-1664. (Pubitemid 47557290)
133. 18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2008; 62: 55-61.
134. Lee KH, Lee SH, Kim DW, et al. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res 2006; 12: 4232-4236.
135. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 8362-8370.
136. Nahmias C, Hanna WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 2007; 48: 744-751. (Pubitemid 47604974)
137. Junker K, Muller KM, Bosse U, et al. Apoptose und Tumor-regression bei neoadjuvant behandelten lokal fortgeschrittenen nichtkleinzelligen Lungenkarzinomen [Apoptosis and tumour regression in locally advanced non-small cell lung cancer with neoadjuvant therapy]. Pathologe 2003; 24: 214-219. (Pubitemid 36676117)
138. Okada M, Nishio W, Sakamoto T, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004; 78: 216-221. (Pubitemid 38833935)
139. Nisman B, Biran H, Heching N, et al. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer 2008; 98: 77-79.
140. Sawabata N, Hirano H, Inoue M, et al. Immunohistochemical analysis of resected clinical stage I pulmonary adenocarcinomas with high preoperative levels of serum carcinoembryonic antigen. Ann Thorac Surg 2003; 76: 203-207. (Pubitemid 36819743)
141. Sawabata N, Maeda H, Yokota S, et al. Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: subnormal levels as an indicator of favorable prognosis. Cancer 2004; 101: 803-809. (Pubitemid 39030938)
142. Sawabata N, Ohta M, Takeda S, et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 2002; 74: 174-179. (Pubitemid 34734668)
143. Bréchot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997; 33: 385-391. (Pubitemid 27168063)
144. Chiu CH, Shih YN, Tsai CM, et al. Serum tumour markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer 2007; 57: 213-221. (Pubitemid 47043179)
145. Spiridonidis CH, Laufman LR, Stydnicki KA, et al. Decline of posttreatment tumour marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor. Cancer 1995; 75: 1586-1593.
146. Hamzaoui A, Thomas P, Castelnau O, et al. Usefulness of longitudinal evaluation of Cyfra 21-1 variations in advanced lung cancer monitoring. Lung Cancer 1997; 16: 191-202. (Pubitemid 27215812)
147. Sunaga N, Tsuchiya S, Minato K, et al. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 1999; 57: 143-148. (Pubitemid 29385493)
148. Okusaka T, Eguchi K, Kasai T, et al. Serum levels of pro-gastrin- releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997; 3: 123-127. (Pubitemid 27079454)
149. Fizazi K, Cojean I, Pignon JP, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 1998; 82: 1049-1055.
150. Gauthier I, Ding K, Winton T, et al. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience. Lung Cancer 2007; 55: 357-363. (Pubitemid 46329181)
151. Laurie SA, Ding K, Whitehead M, et al. The impact of anaemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2007; 18: 1051-1055. (Pubitemid 47050497)
152. Ishikawa N, Hattori N, Yokoyama A, et al. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer 2008; 122: 2612-2620. (Pubitemid 351590499)
153. Chen TF, Jiang GL, Fu XL, et al. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 2007; 56: 105-114.
154. Yamashita J, Matsuo A, Kurusu Y, et al. Preoperative evidence of circulating tumour cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: a prospective study. J Thorac Cardiovasc Surg 2002; 124: 299-305. (Pubitemid 35025606)
155. Buyse M. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J 2009; 15: 421-425.
156. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006; 129: 174-181. (Pubitemid 43265259)